Limit search to available items
Book Cover

Title Therapeutic kinase inhibitors / Ingo K. Mellinghoff, Charles L. Sawyers, editors ; responsible series editor: Peter K. Vogt
Published Heidelberg : Springer Verlag, 2012


Description 1 online resource (x, 234 pages) : illustrations
Series Current topics in microbiology and immunology, 0070-217X ; v. 355
Current topics in microbiology and immunology ; v. 355. 0070-217X
Contents Setting up a Kinase Discovery and Development Project / Gideon Bollag -- Drug Efficacy Testing in Mice / William Y. Kim, Norman E. Sharpless -- Gastrointestinal Stromal Tumors / Cristina Antonescu -- EGFR Mutant Lung Cancer / Yixuan Gong, William Pao -- Targeting Oncogenic BRAF in Human Cancer / Christine A. Pratilas, Feng Xing, David B. Solit -- Beyond BRAF in Melanoma / Adil Daud, Boris C. Bastian -- JAK-Mutant Myeloproliferative Neoplasms / Ross L. Levine -- Will Kinase Inhibitors Make it as Glioblastoma Drugs? / Ingo K. Mellinghoff, Nikolaus Schultz, Paul S. Mischel -- Predictive Genomic Biomarkers / Rakesh Kumar, Rafael G. Amado -- Epigenetic Biomarkers / Timothy A. Chan, Stephen B. Baylin -- Adjuvant Trials of Targeted Agents: The Newest Battleground in the War on Cancer / Robert L. Cohen
Summary Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as "chemotherapy" and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors hope these lessons will be instructive for the novice as well as the expert
Analysis biomedische wetenschappen
Medicine (General)
Geneeskunde (algemeen)
Bibliography Includes bibliographical references and index
Notes Print version record
Subject Cancer -- Chemotherapy.
Antineoplastic agents.
Neoplasms -- drug therapy
Protein Kinase Inhibitors -- therapeutic use
Antineoplastic Agents -- therapeutic use
Drug Discovery
Adenosine Triphosphate -- therapeutic use
MEDICAL -- Pharmacology.
Antineoplastic agents
Cancer -- Chemotherapy
Form Electronic book
Author Mellinghoff, Ingo K
Sawyers, Charles L
ISBN 9783642282966